4219 results about "Drug effect" patented technology

Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.

It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability of the drug contained therein with the passage of time and can achieve improvement in the compliance and simplification of the administration method. These problems can be solved by providing a transdermal absorption patch which contains a basic drug having an octanol/water partition coefficient (logarithm) in the free state of 3 or above, a pressure-sensitive adhesive base and a (meth)acrylic copolymer having carboxyl group.

The invention relates to of medicine and medicine equipment and concerns techniques and means for medicinal action with electromagnetic fields to living tissues. A method provides a stimulating effect of an electromagnetic field to metabolic processes in tissues of an organism, that result in positive shifts of a functional state of regulatory systems. On a contactless electromagnetic action to members of a vascular system, biomechanical, bioelectrical and bioresonant processes in the vascular system control the tone of a vascular wall with a high degree of selectivity. The method and device allow to reduce treatment periods, post-operative and other types of rehabilitation due to a deep contactless interaction of biological tissues of a patient, provided by sensor fields of the organism at an information level, with low-frequency electromagnetic fields that are created by the inventive device with special bioadequate parameters relative to dynamic (that is, time and shape parameters), amplitude and geometric-spatial properties. The inventive device consists of a specialized biosynchronized generator of low-frequency electrical signals that arrive at an electromagnetic inductor converting the electrical signals into electromagnetic fields having given electromagnetic properties determined as a result of fundamental theoretical studies and experiments.

A medical diagnosis system based on big data comprises a diagnosis and treatment scheme database.Information of the diagnosis and treatment scheme database and information of a patient inspection result are combined and transmitted to a prescription generation module.The prescription generation module transmits the information to a patient drug-use module.The patient drug-use module transmits the information to an information feedback module.The information feedback module transmits the information to the diagnosis and treatment scheme database.The patient inspection result can also be transmitted to a patient information base.The diagnosis and treatment scheme database and the patient information base transmit the information to a hospital information system.The big data technology is utilized for building the diagnosis and treatment scheme data, the prescription generation module can synthesize all inspection result data and automatically give out prescription or treatment schemes, drug effect conflicts or drug-use contraindication among drugs can be avoided, curative effect feedback information of a patient is included, communications between a doctor and the patient can be increased, more treatment reference information can be given to the doctor, the patient can go to the doctor conveniently, and medical accidents can be reduced.

The invention provides a method for preparing drug sustained release nanofibers. The method is characterized by including the specific steps that (1) drug-carried micro-spheres are arranged in an organic solvent to be evenly stirred and vibrated to obtain core layer spinning solutions; (2) degradable solutes and volatile solvents are evenly mixed to prepare surface-layer spinning solutions; (3) the surface-layer spinning solutions and the core layer spinning solutions are injected into a surface-layer liquid storage tank and a core layer liquid storage tank of a coaxial spinning jet respectively, coaxial electrostatic spinning is carried out at the room temperature, and the volatile solvents in the surface-layer spinning solutions volatilize to form through holes in the spinning process to obtain the drug sustained release nanofibers with the porous surface layer and the drug-carried micro-sphere wrapped core layer. By means of the method, the obvious multi-stage drug release system is achieved, and the drug-carried micro-spheres are released in the core layer firstly to enter a hole channel in the surface layer and finally enter damaged target components of the nanofibers to give play to drug effects. The method is simple in operation and gentle in reaction condition. A drug sustained release curve is well controlled, and the drug using efficiency is improved.

The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum/plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.

The invention relates to the technical field of nano materials and specifically relates to amino-modified silica with dual drug-loading effects. According to the technical scheme, firstly, mesoporous silica nanoparticles are prepared by a template method; secondly, surface amino modification is carried out onto the mesoporous silica nanoparticles by 3-aminopropyltriethoxy silane; thirdly, ursolic acid is chemically coupled to the spherical mesoporous silica nanoparticles by amido bonds; and fourthly, the coupled nanoparticles are dispersed in DMF (dimethyl formamide) solution; a proper amount of ursolic acid is added, mixed and stirred; and finally vacuum drying is carried out to obtain the amino-modified silica with dual drug-loading effects. The mesoporous nano material with dual drug-loading effects prepared by the mesoporous silica disclosed by the invention is high in loading rate, can achieve controlled release effect for the loading drug ursolic acid, so that drug effect lasts for a long period time, and therefore, bioavailability of the ursolic acid is greatly improved.

The invention discloses a composite throwing applying agent and a preparation method thereof, and the throwing applying agent comprises the following components by weight: 35-90% of composite carrier materials, 2-7% of disease and insect pest-resistant or herbicidal raw drugs, and 3-20% of wood vinegar and tar; wherein the composite carrier materials comprise the following components by weight: 30-80% of organic powder, 5-80% of inorganic powder, 1-10% of moisture-retaining water-retaining agents, 0.1-5.0% of adhesives, proper amounts of water, and 1-10% of plant nutrient elements and/or plant growth regulators; the disease and insect pest-resistant or herbicidal raw drugs comprise one or more than one of insecticidal, bactericidal or herbicidal pesticides or microbial reagents. The invention not only makes every effort to make the application of the throwing applying agent be simple, but also allows the carrier material to have several functions of adsorption, moisture retention, continuous play of the drug effect of the loaded pesticides, and supply of large and medium trace nutrients required by crops.

The present invention relates to a method of culturing peripheral lymphoid organ cells on a three-dimensional scaffolding which is covered or surrounded with culture medium, under conditions effective to generate and maintain mature and functional lymphoid cells, where the three-dimensional scaffolding allows cells in the culture medium to have cell to cell contact in three dimensions. The present invention also provides methods of screening for vaccine candidates for efficacy in eliciting an immune response, identifying genes or proteins which are related to peripheral lymphoid organ cell formation or function, screening for drugs effecting peripheral lymphoid organ cell maturation, treating a patient for a disease condition using antigen-specific lymphoid cells, and effecting gene expression of peripheral lymphoid organ cells.

The invention discloses a phosphorus-free composite scale and corrosion inhibitor, applications thereof, and a processing method for circulating water. The phosphorus-free composite scale and corrosion inhibitor comprises dispersants, phosphorus-free corrosion inhibitors and manganese salts. The weight ratio of the dispersants, the phosphorus-free corrosion inhibitors and the manganese salts is 1:0.5-50:0.025-0.5, wherein the weight of the manganese salts is in terms of manganese ions. The phosphorus-free composite scale and corrosion inhibitor has good synergistic effects with non-oxidation-type bactericides, especially isothiazolinone, and can raise the bactericidal effects of the non-oxidation-type bactericides obviously, the bactericidal speed is rapid and the drug effect time is long. The phosphorus-free composite scale and corrosion inhibitor is environmentally friendly, has phosphorus-free and nitrogen-free characteristics, meets green environmental protection requirements, and reduces environmental burden. The phosphorus-free composite scale and corrosion inhibitor has a wide water quality adaptation range, and is easy to be popularized and applied.

The invention discloses an axially chiral R-enantiomer and an axially chiral S-enantiomer of the drug Lesinurad. The axially chiral R-enantiomer shows excellent URAT1 inhibition effect, overcomes the problems that a high dosage of Lesinurad racemate leads to renal toxicity and a low dosage Lesinurad racemate cannot produce additional drug effect, and can be applied to treatment or prevention of symptoms of abnormal tissue uric acid levels.

A system for monitoring drug dispensation and drug effects on physiological signals or implantable medical device (IMD) performance is provided. The system includes a drug dispenser adapted for telemetric communication with an IMD, an IMD capable of acquiring time-based physiological or device performance data, and a programmer/monitor for receiving and displaying IMD-acquired data and drug dispensation data. The system may further include a patient activator for transmitting signals indicative of symptoms experienced by a patient associated with a side-effect caused by a drug or a condition for which the drug has been prescribed to treat. In an associated method, a drug dispensation signal is generated upon activation of the drug dispenser. IMD-acquired data, drug dispensation data, and patient symptom data are retrieved by a programmer/monitor. IMD-acquired data is combined with or grouped according to drug dispensation data and displayed.

The invention relates to fusion protein used to prevent and cure I type and II type diabetes and its preparation method and application. It supplies the fusion protein which is formed by glucagon analogy peptide GLP-1, GLP-1 mutant and IgG-Fc, its analogy factor lizard salivary gland polypeptide extendin-4 and IgG-Fc, and the application of the above fusion protein and its DNA used in diabetes prevention and therapy. The fusion protein can increase not only GLP-1 effect, but also the affinity and immunological tolerance of ligand, which is excreted with the form of homogeneity dimmer to improve polypeptide drug effect, overcomes the defect of the GLP-1 for short half-life, and simplifies purification process.

The invention discloses an anti-human CLDN18.2 antibody as well as an antigen binding fragment and a medical application thereof. Specifically, the present invention relates to a murine antibody comprising a CDR region of the anti-human CLDN18.2 antibody, a chimeric antibody and a humanized antibody, a fully humanized antibody, an antibody-dependent cytotoxicity (ADCC) comprising the antibody andthe antigen binding fragment thereof, complement dependent cytotoxicity (CDC), the killing effect on CLDN18.2 positive cells, the effect of inhibiting the growth of CLDN18.2 positive tumors, the in-vivo drug effect, a medicine containing the anti-human CLDN18.2 antibody and the antigen binding fragment thereof, a composition of the medicine thereof, and an application of the medicine in tumor treatment, in particular to treatment of CLDN18.2 positive tumor patients..

The invention relates to detection of anomalies related to a measurement of the hypnotic level of a subject. In order to detect when a measure indicative of the hypnotic level of a subject is anomalous either due to a medical reason or due to an interference, the measure is monitored and state information indicative of the activity of the autonomous nervous system of the subject and drug effect information indicative of the hypnotic drug effect in the subject are employed to check whether the measure fulfills a predetermined consistency condition requiring that the measure changes consistently with at least one of the drug effect information and the state information. An anomaly, indicative of an abnormal change in the measure, is detected when the measure fails to fulfill the predetermined consistency condition.

The invention provides icariin application in inducing stem cell in vitro orientation differentiates to several single type cells. The stem cell said includes embryonic stem cell, nerve stem cell and marrow mesenchyme stem cell. The single type cell includes nerve cell, bone cell, islet cells and endothelial cell. This invention also relates to application of the single type cell in preparing medicine of stem cell transplant curing nerve degenerative diseases, and its application in preparing cell differentiation agent that used to repair recovery injured nerve tissue, and its application in high efficiency drug effect screening model rebuilding and initial screening and estimating by using the model. The new applications of the icariin is extended in this invention, the fact of icariin contains pharmacy activity clarified, so it provides material basis for Chinese traditional medicine prevention and cure effect. The clarifying of drug effect mechanism provides reference for new medicine Chinese metical modern development with self-owned intellectual property right.

The invention belongs to the field of medicine, and relates to D-configuration polypeptide with high stability and capable of realizing mediated targeting of acetylcholine receptor high-expression cells and crossing corresponding barrier membranes and a nano drug delivery system thereof as well as an application in in-vivo and in-vitro brain targeting and in treatment of brain diseases and the like. Test results indicate that DCDX and the acetylcholine receptor are combined with IC50 to obtain 84.5nM which is stable in serum and tolerates hydrolysis of protease; the model drug carried by DCDX is specifically taken in by the positive cells expressing the acetylcholine receptor and has an ability of crossing the barrier formed by the kind of cells; and the nano drug delivery system made of a DCDX-modified polymer carrier material can deliver the entrapped model drug to the target tissue while the drug effect is remarkably improved. The D-configuration polypeptide DCDX provided by the invention can mediate active targeting of the drug or nano drug delivery system and has a good application prospect in the diagnosis and treatment of multiple diseases.

The invention discloses a medicative fertilizer preparation which is developed by the scientific combination of insecticide and fertilizer. The medicative fertilizer comprises the insecticidal components such as carbosulfan and tebufenozide, nitrogen-potassium-phosphate fertilizer, trace elements and a stabilizing agent, wherein a mixed preparation of the carbosulfan and the tebufenozide has the characteristics of high biological activity, good drug effect, little possibility of resistibility and the like for the soil insects of sugarcane stem borers, white grubs, alissonotum impressicolle arrow and the like. Meanwhile, the medicative fertilizer preparation is also a very good crop growth regulation fertilizer, has double effects of medicine and fertilizer and is labour-saving, time-saving, labor-saving and money-saving. The invention has stable chemical property; the invention features safe, simple and convenient use, little dosage, long lasting time of the drug effect and extensive application prospect, lightens labor strength and the labor time of a farmer, has a great significance for effectively, scientifically and reasonably utilizing resources and protecting the environmentand also acts as a positive boost for reducing the agricultural investment of a user and increasing the yield and the benefit of agriculture.

The invention discloses a biodegradable liquid agricultural film, and relates to a liquid ground film. The invention aims at solving the problems that the current liquid ground film contains a great amount of petrol derivatives, is not easy to be degraded, can harden soil and generate toxicity after a long term application, and that the raw material resource is limited and the cost is comparatively high. The liquid agricultural film of the invention is made from 10 portions to 50 portions of plant straw, more than 0 portion to 30 portions of humic acid, 30 portions to 70 portions of water, 3 portions to 15 portions of film-forming agent, 0.5 portion to 1 portion of surfactant, more than 0 portion to 20 portions of fertilizer and more than 0 portion to 20 portions of stabilizer by weight. The liquid agricultural film of the invention can be made by the spraying of ordinary sprayers, thus saving labor, time and energy and avoiding the operations of seedling placing and waste film collection. After 2 months to 3 months, the agricultural film starts to be degraded into organic fertilizer of humic acid and the final degradation product is carbon dioxide and water. The agricultural film can be complexed with fertilizers and pesticide to prolong the fertilization effect and drug effect. The ground temperature can be increased by 1 DEG C to 6 DEG C and the crop output can be increased by 6 percent to 50 percent.

The invention relates to a cloud-computing-based health management system comprising cloud service modules (200) and terminals in communication connection with the cloud service modules (200) by a network. Each cloud service module (200) consists of a database (201), a database management server (202), a data analysis server (203) and a transaction processing server (204), a plurality of access servers (206) for terminal access, and a message push server (205); the data analysis server (203) and the transaction processing server (204) access the database (201) by the database management server (202); and the message push server (205) and the transaction processing server (204) are in interaction of transactional messages and the message push server (205) and the access servers (206) are in interaction of data/ transactional messages. Besides, the terminals contain monitoring terminals (300), management terminals (330) and gateway terminals (340); and a user of each terminal has an ID registered at the database (201). With the system and method, medicine application can be set and prompted; physiological parameters can be monitored comprehensively; and a medicine taking plan can be optimized based on a drug effect analysis.

The invention discloses a technology for improving the drug effects of Mythic Fungus and Chinese angelica through utilizing Mythic Fungus-Chinese angelica bidirectional fermentation. The technology comprises the steps of Chinese angelica pretreatment, Mythic Fungus strain activation, culturing medium preparation, bidirectional fermentation, and fermentation extraction and use. The purpose of the invention is enhancing the biological activities and drug effects of Mythic Fungus and Chinese angelica, and the oxidation resistance activity of Chinese angelica is improved 60-100 times after fermentation. Mythic Fungus and Chinese angelica can be used as functional foods and medicines for strengthening the body resistance and prolonging the life, and have good application prospects.

The invention provides a collagen and a collagen polypeptide, wherein, the weight percentage of hydroxylysine is more than 1.3 percent. The invention also provides the preparation technology and the application of the collagen and the collagen polypeptide. The invention can make full use of inexpensive raw materials including the fish skin and fish scale of tilapias to produce products with high added value. The collagen polypeptide is used for treating arthritis with a definite drug effect, and the clinical dose is considerably less than other collagen polypeptides. The collagen polypeptide can solve the pollution problem of fish skin wastes, and at the same time avoid the risk of infectious diseases which can be caused by the collagen of land animals. The collagen and the collagen polypeptide have the advantages of considerable economic benefits, energy conservation and environmental protection, simple process equipment, low cost and easy industrialization.